Overall, these findings suggest that salvage ipilimumab plus nivolumab has meaningful clinical activity in select patients with advanced HCC who failed prior anti-PD-(L)1 therapy, including regimens incorporating anti-VEGF agents. This evidence concerns the gene VEGFA and hepatocellular carcinoma.